Personalized drug screening for functional tumor profiling:
Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements obse...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, United Kingdom ; New York, NY, USA
Cambridge University Press
2022
|
| Schriftenreihe: | Cambridge elements: elements in molecular oncology
|
| Schlagworte: | |
| Online-Zugang: | Cover original |
| Zusammenfassung: | Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology |
| Beschreibung: | 22 Seiten Illustration 151 x 228 mm |
| ISBN: | 9781009016933 1009016938 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049346255 | ||
| 003 | DE-604 | ||
| 005 | 20240131 | ||
| 007 | t | ||
| 008 | 230929s2022 a||| |||| 00||| eng d | ||
| 020 | |a 9781009016933 |c Broschur : EUR 20.95 |9 978-1-00-901693-3 | ||
| 020 | |a 1009016938 |9 1-00-901693-8 | ||
| 024 | 3 | |a 9781009016933 | |
| 035 | |a (OCoLC)1422497242 | ||
| 035 | |a (DE-599)BVBBV049346255 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XH 3190 |0 (DE-625)152887:12999 |2 rvk | ||
| 100 | 1 | |a El-Khoury, Victoria |d 1977- |e Verfasser |0 (DE-588)1264159633 |4 aut | |
| 245 | 1 | 0 | |a Personalized drug screening for functional tumor profiling |c Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health) |
| 264 | 1 | |a Cambridge, United Kingdom ; New York, NY, USA |b Cambridge University Press |c 2022 | |
| 300 | |a 22 Seiten |b Illustration |c 151 x 228 mm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Cambridge elements: elements in molecular oncology | |
| 520 | |a Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology | ||
| 650 | 4 | |a Medicine: general issues / BIC2 | |
| 650 | 4 | |a Oncology / BIC2 | |
| 700 | 1 | |a Michel, Tatiana |d 1975- |e Verfasser |0 (DE-588)1264160062 |4 aut | |
| 700 | 1 | |a Kim, Hichul |d 1976- |e Verfasser |0 (DE-588)1264160437 |4 aut | |
| 700 | 1 | |a Kwon, Yong-Jun |d 1976- |e Verfasser |0 (DE-588)1264160739 |4 aut | |
| 856 | 4 | |u https://www.lehmanns.de/media/104110993 |y Cover original | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034606724 | ||
Datensatz im Suchindex
| _version_ | 1804185875716767744 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | El-Khoury, Victoria 1977- Michel, Tatiana 1975- Kim, Hichul 1976- Kwon, Yong-Jun 1976- |
| author_GND | (DE-588)1264159633 (DE-588)1264160062 (DE-588)1264160437 (DE-588)1264160739 |
| author_facet | El-Khoury, Victoria 1977- Michel, Tatiana 1975- Kim, Hichul 1976- Kwon, Yong-Jun 1976- |
| author_role | aut aut aut aut |
| author_sort | El-Khoury, Victoria 1977- |
| author_variant | v e k vek t m tm h k hk y j k yjk |
| building | Verbundindex |
| bvnumber | BV049346255 |
| classification_rvk | XH 3190 |
| ctrlnum | (OCoLC)1422497242 (DE-599)BVBBV049346255 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02634nam a2200385 c 4500</leader><controlfield tag="001">BV049346255</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240131 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">230929s2022 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781009016933</subfield><subfield code="c">Broschur : EUR 20.95</subfield><subfield code="9">978-1-00-901693-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1009016938</subfield><subfield code="9">1-00-901693-8</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9781009016933</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1422497242</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049346255</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3190</subfield><subfield code="0">(DE-625)152887:12999</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">El-Khoury, Victoria</subfield><subfield code="d">1977-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1264159633</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalized drug screening for functional tumor profiling</subfield><subfield code="c">Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, United Kingdom ; New York, NY, USA</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">22 Seiten</subfield><subfield code="b">Illustration</subfield><subfield code="c">151 x 228 mm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cambridge elements: elements in molecular oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine: general issues / BIC2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology / BIC2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Michel, Tatiana</subfield><subfield code="d">1975-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1264160062</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Hichul</subfield><subfield code="d">1976-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1264160437</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kwon, Yong-Jun</subfield><subfield code="d">1976-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1264160739</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="u">https://www.lehmanns.de/media/104110993</subfield><subfield code="y">Cover original</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034606724</subfield></datafield></record></collection> |
| id | DE-604.BV049346255 |
| illustrated | Illustrated |
| index_date | 2024-07-03T22:48:24Z |
| indexdate | 2024-07-10T10:02:11Z |
| institution | BVB |
| isbn | 9781009016933 1009016938 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034606724 |
| oclc_num | 1422497242 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 22 Seiten Illustration 151 x 228 mm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Cambridge University Press |
| record_format | marc |
| series2 | Cambridge elements: elements in molecular oncology |
| spelling | El-Khoury, Victoria 1977- Verfasser (DE-588)1264159633 aut Personalized drug screening for functional tumor profiling Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health) Cambridge, United Kingdom ; New York, NY, USA Cambridge University Press 2022 22 Seiten Illustration 151 x 228 mm txt rdacontent n rdamedia nc rdacarrier Cambridge elements: elements in molecular oncology Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology Medicine: general issues / BIC2 Oncology / BIC2 Michel, Tatiana 1975- Verfasser (DE-588)1264160062 aut Kim, Hichul 1976- Verfasser (DE-588)1264160437 aut Kwon, Yong-Jun 1976- Verfasser (DE-588)1264160739 aut https://www.lehmanns.de/media/104110993 Cover original |
| spellingShingle | El-Khoury, Victoria 1977- Michel, Tatiana 1975- Kim, Hichul 1976- Kwon, Yong-Jun 1976- Personalized drug screening for functional tumor profiling Medicine: general issues / BIC2 Oncology / BIC2 |
| title | Personalized drug screening for functional tumor profiling |
| title_auth | Personalized drug screening for functional tumor profiling |
| title_exact_search | Personalized drug screening for functional tumor profiling |
| title_exact_search_txtP | Personalized drug screening for functional tumor profiling |
| title_full | Personalized drug screening for functional tumor profiling Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health) |
| title_fullStr | Personalized drug screening for functional tumor profiling Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health) |
| title_full_unstemmed | Personalized drug screening for functional tumor profiling Victoria El-Khoury (Luxembourg Institute of Health), Tatiana Michel (Luxembourg Institute of Health), Hichul Kim (Luxembourg Institute of Health), Yong-Jun Kwon (Luxembourg Institute of Health) |
| title_short | Personalized drug screening for functional tumor profiling |
| title_sort | personalized drug screening for functional tumor profiling |
| topic | Medicine: general issues / BIC2 Oncology / BIC2 |
| topic_facet | Medicine: general issues / BIC2 Oncology / BIC2 |
| url | https://www.lehmanns.de/media/104110993 |
| work_keys_str_mv | AT elkhouryvictoria personalizeddrugscreeningforfunctionaltumorprofiling AT micheltatiana personalizeddrugscreeningforfunctionaltumorprofiling AT kimhichul personalizeddrugscreeningforfunctionaltumorprofiling AT kwonyongjun personalizeddrugscreeningforfunctionaltumorprofiling |